Allergan Buys Vicept Therapeutics

Allergan is buying privately held dermatology company Vicept Therapeutics. Formed in 2009, Vicept is backed by investors including Vivo Ventures, Fidelity Biosciences and Sofinnova Ventures. Under the terms of the acquisition, which is expected to close during the third quarter, Allergan will pay $75 million in cash up-front, as well as up to $200 million in payments tied to specific milestones.

North AmericaUSBriefs